Quantitative Concept – Page 32

Revolutionizing Clinical Trials: Leveraging AI for Enhanced Efficiency and Accuracy

11 months ago talkbio0Tagged Accurate (qualifier), AI-Powered Tools, Artificial Intelligence, Auditory recruitment, Clinical Trials, Data Analysis, Efficiency, Precision Medicine

Artificial Intelligence, Clinical Trials, Data Analysis, Patient Recruitment, Personalized Medicine, AI-Powered Tools, Medical Research, Efficiency, Accuracy

GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

11 months ago talkbio0Tagged Adult, Age, Approved, Arexvy, Asthma, Chronic Obstructive Airway Disease, Diabetes, Heart failure, Increased, medical conditions, Respiratory syncytial virus, Respiratory Tract Diseases, Risk, SmithKline Beecham, United States Food and Drug Administration, Vaccines

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.

Skye Bioscience Abandons Eye Disease Pipeline, Shifts Focus to Obesity Treatment After Phase 2a Trial Failure

11 months ago talkbio0Tagged Bioscience, biotech company, Obesity, Prices, Skye, Trial Phase 2A

Skye Bioscience, eye disease, Phase 2a trial, obesity treatment, stock price, biotech company

Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance

11 months ago talkbio0Tagged Dry Eye Syndromes, Licaminlimab, Oculis, Phase 2, Statistical Significance

Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance

Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign

11 months ago talkbio0Tagged Drug Industry, Financial cost, Financial savings, Myers, New Jersey, savings campaign, squibb

Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry

Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook

11 months ago talkbio0Tagged Biopharma, Capital, Federal Interest Rates, Levels (qualifier value), venture

Biopharma, Funding Levels, Federal Interest Rates, PitchBook, Venture Capital

ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

11 months ago talkbio0Tagged Acquisition (action), Alphamab, ArriVent, Biotechnology, financing characteristics, portfolio, therapeutic autologous dendritic cells

ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing

RYBREVANT: A Breakthrough in Lung Cancer Treatment

11 months ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)